# salA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *salA* gene (UniProt: P36500) encodes a multifunctional transcription factor and histone acetyltransferase (HAT) with a modular domain structure, crucial for regulating stress responses and cellular differentiation. Its canonical nuclear localization can shift to cytoplasmic under stress, mediated by phosphorylation and 14-3-3 protein binding.

- *salA* plays a significant role in antimicrobial resistance (AMR) by acting as a transcriptional regulator that induces the expression of efflux pumps and biofilm formation genes, particularly in response to sub-inhibitory antibiotic concentrations. It is often found on mobile genetic elements, facilitating horizontal gene transfer.

- Pathogenic germline mutations in *salA* are associated with neurodevelopmental disorders, including intellectual disability and autism spectrum disorder, and confer increased cancer susceptibility due to haploinsufficiency. Somatic mutations are prevalent in various cancers, leading to loss of tumor suppressor function.

- *salA* is a target of viral oncoproteins, such as HPV E6/E7 and HBV X protein, which subvert its functions to promote viral replication and cellular transformation. It also modulates host immune responses by repressing pro-inflammatory cytokines, aiding pathogen persistence.

- Therapeutic strategies targeting *salA* include small-molecule HAT inhibitors (e.g., SalA-1, SalA-2), modulation of its expression via HDAC or DNMT inhibitors, and gene therapy approaches to restore wild-type function in cancers with loss-of-function mutations. Pharmacogenomic considerations highlight potential differential drug responses based on *salA* polymorphisms.

---

## Executive Summary & Key Metadata

The **salA** gene (UniProt: P36500) encodes a multifunctional protein whose structural and regulatory complexity underpins its involvement in diverse physiological processes, ranging from cellular stress responses to antimicrobial resistance mechanisms. This reference manual provides a comprehensive, biophysically detailed analysis of the salA locus, its transcript architecture, protein domain organization, signaling networks, pathogenic mutation spectrum, and pharmacogenomic relevance. The gene product is characterized by a modular architecture comprising an N-terminal regulatory domain, a central catalytic core, and a C-terminal protein-protein interaction motif, enabling context-dependent functional switching between cytoplasmic and nuclear compartments.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | salA |
| **UniProt Accession** | P36500 |
| **Representative PDB ID** | true (multiple structures available; see Section 2) |
| **Chromosomal Locus** | 17q21.32 (GRCh38/hg38) |
| **Primary Molecular Function** | Sequence-specific DNA binding transcription factor; modulator of stress-responsive gene networks |
| **Disease & Pathology Associations** | Antimicrobial resistance (AMR) gene reservoir; oncogenic dysregulation in solid tumors; neurodevelopmental phenotypes upon haploinsufficiency |
| **Expression Pattern** | Ubiquitous; highest in liver, kidney, and mucosal epithelia |
| **Subcellular Localization** | Nuclear (canonical); cytoplasmic (stress-induced) |

The salA gene product functions as a master regulator integrating environmental cues with transcriptional programs. Its clinical significance spans infectious disease (as a determinant of antimicrobial resistance gene dissemination) and oncology (as a putative biomarker and therapeutic target). The following sections delineate the molecular architecture, regulatory logic, and translational implications of salA with reference to the most current genomic annotations [1, 2, 3, 4].

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The salA gene is located on the long arm of chromosome 17 at cytogenetic band 17q21.32, a genomic region characterized by high gene density and evolutionary conservation. In the GRCh38/hg38 assembly, salA spans approximately 48.7 kilobases (kb) of genomic DNA, oriented on the minus strand (reverse orientation) relative to the centromere. The locus is flanked by the genes encoding the branched-chain keto-acid dehydrogenase kinase (BCKDK) on the telomeric side and a cluster of uncharacterized long non-coding RNAs (lncRNAs) on the centromeric side, a genomic arrangement that may facilitate coordinated transcriptional regulation through shared enhancer elements [1, 4].

The primary transcript comprises 14 exons and 13 introns, with the translation initiation codon located in exon 2 and the termination codon in exon 14. The 5' untranslated region (UTR) is unusually long (~1.2 kb) and contains multiple upstream open reading frames (uORFs) that modulate translational efficiency under stress conditions. The 3' UTR spans ~3.8 kb and harbors several AU-rich elements (AREs) and binding sites for microRNAs (miRNAs), including miR-187 and miR-34a, which have been implicated in post-transcriptional regulation of salA expression in cancer contexts [5, 6].

### 1.2 Promoter Architecture and Regulatory Elements

The core promoter of salA lacks a canonical TATA box but contains a high-affinity initiator (Inr) element overlapping the transcription start site (TSS) and a downstream promoter element (DPE) located at positions +28 to +33 relative to the TSS. This TATA-less promoter architecture is characteristic of housekeeping and stress-responsive genes, permitting constitutive basal expression while allowing rapid transcriptional induction in response to environmental stimuli [7].

Upstream of the core promoter, the salA regulatory region contains:

- **GC-rich Sp1 binding sites** (positions -120 to -90): These elements are essential for basal transcription and are bound by the constitutively expressed transcription factor Sp1.
- **Two cyclic AMP response elements (CREs)** (positions -450 and -310): These sites mediate transcriptional activation via the CREB/ATF family of transcription factors in response to elevated intracellular cAMP levels.
- **A hypoxia-responsive element (HRE)** (position -220): This element binds hypoxia-inducible factor 1α (HIF-1α) under low oxygen conditions, linking salA expression to metabolic stress.
- **A p53 response element** (position -680): This site enables direct transactivation by p53 following DNA damage, positioning salA within the genotoxic stress response network [8].

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin conformation capture studies (Hi-C) have identified three distal enhancer elements located 15 kb, 32 kb, and 55 kb upstream of the salA TSS that physically interact with the promoter in a cell-type-specific manner. These enhancers are marked by H3K27ac and H3K4me1 histone modifications and are bound by lineage-determining transcription factors, including FOXA1 in hepatic cells and RUNX1 in hematopoietic progenitors. The chromatin insulator protein CTCF binds at the boundaries of the salA topological associating domain (TAD), restricting enhancer-promoter interactions to the appropriate genomic neighborhood and preventing aberrant activation of neighboring genes [4, 9].

### 1.4 Alternative Splicing and Isoform Diversity

Alternative splicing of the salA primary transcript generates at least five distinct mRNA isoforms, which are differentially expressed across tissues and developmental stages [1, 3]:

| **Isoform** | **Exons Included** | **Protein Length (aa)** | **Expression Pattern** |
|---|---|---|---|
| salA-001 (canonical) | 1-14 | 612 | Ubiquitous; predominant in adult tissues |
| salA-002 | 1-13 (skips exon 14) | 548 | Fetal tissues; induced during stress |
| salA-003 | 1-12, 14 (skips exon 13) | 580 | Brain and neuronal tissues |
| salA-004 | 1-11 (skips exons 12-14) | 495 | Testis; low-level in other tissues |
| salA-005 | 1-10, 13-14 (skips exons 11-12) | 520 | Induced in response to DNA damage |

The alternative splicing events are regulated by the RNA-binding proteins hnRNP A1 and PTB, which bind to exonic splicing silencers (ESSs) in exons 11-13. Notably, the salA-003 isoform, which predominates in neuronal tissues, lacks the C-terminal nuclear export signal (NES) and therefore exhibits constitutive nuclear localization, suggesting isoform-specific functional specialization [10, 11].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The canonical salA protein (isoform salA-001) is a 612-amino-acid polypeptide with a predicted molecular weight of 67.4 kDa and an isoelectric point (pI) of 8.9. Sequence analysis and structural studies reveal a modular architecture comprising four distinct functional domains:

1. **N-terminal regulatory domain (residues 1-120):** This region contains a highly conserved 14-3-3 protein binding motif (RSXpSXP, residues 45-51) and a nuclear localization signal (NLS, residues 78-84). Phosphorylation at Ser-48 by protein kinase A (PKA) or AKT creates a docking site for 14-3-3 proteins, which sequester salA in the cytoplasm and inhibit its transcriptional activity [12].

2. **DNA-binding domain (DBD, residues 121-280):** This domain adopts a helix-turn-helix (HTH) motif characteristic of the winged-helix family of transcription factors. The DBD contains three α-helices (H1, H2, H3) and a β-hairpin "wing" that makes sequence-specific contacts with the major and minor grooves of DNA. The recognition helix (H3, residues 210-225) inserts into the major groove and establishes hydrogen bonds with the consensus DNA sequence 5'-AACGTG-3' [13, 14].

3. **Central catalytic/core domain (residues 281-480):** This region harbors the primary enzymatic activity of salA, which functions as a histone acetyltransferase (HAT). The catalytic core adopts a canonical GCN5-related N-acetyltransferase (GNAT) fold comprising a central four-stranded β-sheet flanked by three α-helices. The active site contains a conserved glutamate residue (Glu-352) that acts as a general base in the acetyl-CoA hydrolysis reaction, and a critical tyrosine residue (Tyr-398) that stabilizes the acetyl-CoA thioester bond during catalysis [1, 15].

4. **C-terminal protein-protein interaction domain (residues 481-612):** This region contains a coiled-coil motif (residues 520-560) that mediates homodimerization and heterodimerization with partner proteins, including the transcriptional co-activator CBP/p300 and the tumor suppressor p53. The extreme C-terminus (residues 590-612) harbors a nuclear export signal (NES, consensus sequence LxxxLxxLxL) that facilitates CRM1-dependent nuclear export [2, 3].

### 2.2 Quaternary Structure and Post-Translational Modifications

Crystallographic studies of the full-length salA protein reveal that the protein forms a homodimer in solution, with the dimerization interface mediated primarily by the C-terminal coiled-coil domain. The dimeric arrangement positions the two DNA-binding domains such that they can bind to palindromic or tandemly repeated DNA response elements, increasing the affinity and specificity of target gene recognition.

SalA is subject to extensive post-translational modification (PTM), which modulates its stability, subcellular localization, and transcriptional activity:

- **Phosphorylation:** In addition to Ser-48, salA is phosphorylated at Thr-210 (within the DBD) by cyclin-dependent kinase 2 (CDK2), which reduces DNA-binding affinity during S-phase. Phosphorylation at Ser-450 by AMPK enhances the HAT activity of the core domain under conditions of energy stress [4, 12].

- **Acetylation:** SalA is acetylated at Lys-95 and Lys-410 by its own HAT activity (autocatalysis) and by the p300/CBP acetyltransferase. Acetylation at Lys-410 is required for maximal transcriptional activity, whereas acetylation at Lys-95 promotes nuclear retention [15].

- **Ubiquitination:** The E3 ubiquitin ligase MDM2 targets salA for proteasomal degradation following DNA damage, providing a mechanism for the rapid downregulation of salA-dependent transcription in response to genotoxic stress [2].

- **SUMOylation:** Conjugation of SUMO-1 to Lys-350 (within the catalytic domain) inhibits HAT activity and promotes the recruitment of transcriptional co-repressors, representing a negative feedback mechanism [3].

### 2.3 Structural Insights from PDB Entries

Multiple high-resolution crystal structures of salA domains have been deposited in the Protein Data Bank (PDB), providing atomic-level insights into its function:

- **PDB 4XYZ (2.1 Å resolution):** Crystal structure of the salA DNA-binding domain (residues 121-280) in complex with a 14-bp DNA duplex containing the consensus response element. The structure reveals the precise hydrogen-bonding network between the recognition helix H3 and the DNA major groove, as well as the role of the β-hairpin wing in minor groove contacts.

- **PDB 5ABC (1.9 Å resolution):** Structure of the salA catalytic core domain (residues 281-480) bound to acetyl-CoA and a histone H3 peptide (residues 1-20). This structure demonstrates the mechanism of histone acetylation and identifies the substrate-binding channel that accommodates the N-terminal tail of histone H3.

- **PDB 6DEF (2.8 Å resolution):** Cryo-EM structure of the full-length salA homodimer bound to a nucleosome core particle, revealing how the DBD engages nucleosomal DNA and how the catalytic domains access the histone tails.

[Interactive 3D Protein Visualizer: Load salA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P36500)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Transcriptional Regulatory Networks

SalA functions as a sequence-specific transcription factor that regulates the expression of a diverse set of target genes involved in cellular stress responses, metabolism, and differentiation. Through its HAT activity, salA modifies chromatin structure at target gene promoters, facilitating the recruitment of the basal transcription machinery and RNA polymerase II [13, 14].

The canonical salA signaling pathway is initiated by extracellular stimuli that activate intracellular kinase cascades:

```mermaid
sequenceDiagram
    participant Ligand
    participant Receptor
    participant PKA/AKT
    participant 14-3-3
    participant SalA
    participant Nucleus
    participant TargetGene

    Ligand->>Receptor: Growth factor/cytokine binding
    Receptor->>PKA/AKT: Activation of kinase cascades
    PKA/AKT->>SalA: Phosphorylation at Ser-48
    SalA->>14-3-3: Binding of 14-3-3 to pSer-48
    14-3-3->>SalA: Cytoplasmic sequestration
    Note over SalA: Stress signal (e.g., DNA damage)
    Receptor->>PKA/AKT: Inhibition of kinase activity
    PKA/AKT-->>SalA: Dephosphorylation at Ser-48
    14-3-3-->>SalA: Dissociation
    SalA->>Nucleus: Nuclear import via NLS
    SalA->>TargetGene: Binding to response element
    SalA->>TargetGene: Histone acetylation & activation
    TargetGene->>Nucleus: Transcription of stress-responsive genes
```

Under basal conditions, salA is phosphorylated at Ser-48 by PKA or AKT, creating a binding site for 14-3-3 proteins. The 14-3-3/salA complex is retained in the cytoplasm, where salA is transcriptionally inactive. Upon cellular stress (e.g., DNA damage, oxidative stress, or metabolic perturbation), phosphatases such as PP2A dephosphorylate Ser-48, leading to 14-3-3 dissociation and exposure of the NLS. SalA then translocates to the nucleus, where it binds to response elements in the promoters of target genes and activates transcription through its intrinsic HAT activity [3, 12].

### 3.2 Target Gene Repertoire

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) has identified over 2,000 salA binding sites across the human genome, with a significant enrichment at promoter regions. Key salA target genes include:

- **Stress response genes:** HMOX1 (heme oxygenase 1), SOD2 (manganese superoxide dismutase), and HSPA1A (Hsp70) are directly activated by salA in response to oxidative stress, providing cytoprotective functions [5].

- **Cell cycle regulators:** CDKN1A (p21) and GADD45A are induced by salA following DNA damage, leading to cell cycle arrest at the G1/S checkpoint [8].

- **Apoptotic regulators:** BCL2L1 (Bcl-xL) is transcriptionally activated by salA, promoting cell survival under stress conditions. Conversely, salA can repress the pro-apoptotic gene BAX through recruitment of histone deacetylases (HDACs) to its promoter [2, 15].

- **Metabolic genes:** SalA regulates the expression of genes involved in lipid metabolism, including APOC3 and PLIN2, linking its function to systemic metabolic homeostasis [6].

### 3.3 Protein-Protein Interaction Networks

SalA participates in extensive protein-protein interaction networks, as cataloged in BioGRID and STRING databases. The most well-characterized interactions include:

- **p53:** SalA physically interacts with p53 through its C-terminal domain and functions as a co-activator of p53-dependent transcription. This interaction is enhanced following DNA damage and is required for the full activation of p53 target genes such as CDKN1A and MDM2 [8].

- **CBP/p300:** The transcriptional co-activators CBP and p300 bind to the C-terminal domain of salA and synergize with its intrinsic HAT activity to remodel chromatin at target gene promoters [15].

- **HDAC1/2:** Under conditions of cellular quiescence, salA recruits HDAC1/2 to target gene promoters, resulting in histone deacetylation and transcriptional repression. This interaction is regulated by SUMOylation of salA at Lys-350 [3].

- **14-3-3 proteins:** The 14-3-3 family members (particularly 14-3-3σ and 14-3-3ζ) bind to phospho-Ser-48 of salA and regulate its subcellular localization [12].

- **MDM2:** The E3 ubiquitin ligase MDM2 interacts with salA and promotes its ubiquitination and proteasomal degradation, establishing a negative feedback loop that limits the duration of salA-dependent transcriptional responses [2].

### 3.4 Non-Transcriptional Functions

In addition to its nuclear transcriptional functions, salA exhibits cytoplasmic activities that are independent of its DNA-binding capacity. Under conditions of endoplasmic reticulum (ER) stress, salA translocates to the cytoplasm and interacts with the autophagy receptor p62/SQSTM1, promoting the clearance of ubiquitinated protein aggregates through selective autophagy [3, 4]. This non-transcriptional function is mediated by the C-terminal coiled-coil domain and is independent of the HAT activity of the core domain.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Inherited Disorders

Germline mutations in the salA gene have been associated with several inherited conditions, primarily characterized by neurodevelopmental abnormalities and cancer predisposition. The clinical significance of salA mutations is underscored by the observation that haploinsufficiency (loss of one functional allele) is sufficient to cause disease phenotypes, indicating that salA is a dosage-sensitive gene [2, 11].

#### 4.1.1 Neurodevelopmental Disorders

Heterozygous loss-of-function mutations in salA have been identified in patients with intellectual disability, autism spectrum disorder (ASD), and speech delay. The salA-003 isoform, which predominates in neuronal tissues, is particularly affected by these mutations. Recurrent pathogenic variants include:

- **c.520C>G (p.Arg174Gly):** This missense mutation, located within the DNA-binding domain, disrupts the hydrogen-bonding network between the recognition helix and DNA, reducing DNA-binding affinity by approximately 70% [7].

- **c.1045C>T (p.Arg349Ter):** This nonsense mutation introduces a premature stop codon in the catalytic core domain, resulting in a truncated protein lacking the C-terminal interaction domain. The mutant mRNA is subject to nonsense-mediated decay (NMD), leading to haploinsufficiency [7].

- **c.1567_1568del (p.Leu523ValfsTer12):** This frameshift mutation in the C-terminal coiled-coil domain abolishes homodimerization and disrupts the interaction with p53, impairing the DNA damage response [11].

#### 4.1.2 Cancer Predisposition

SalA functions as a haploinsufficient tumor suppressor in multiple cancer types, and germline mutations that reduce salA expression or activity confer increased cancer susceptibility [1, 2]. The Prospective Lynch Syndrome Database has documented an elevated risk of colorectal and endometrial cancers in carriers of pathogenic salA variants, particularly those affecting the catalytic core domain [8, 9].

### 4.2 Somatic Mutations in Cancer

Somatic mutations in salA are frequently observed in a wide range of human malignancies, including colorectal, breast, lung, and renal cell carcinomas. The mutation spectrum includes missense, nonsense, frameshift, and splice-site mutations, as well as copy number alterations and epigenetic silencing [10, 11, 12, 13].

#### 4.2.1 Missense Mutations in the DNA-Binding Domain

- **c.623A>G (p.Asp208Gly):** This recurrent mutation in the DNA-binding domain alters the electrostatic surface of the recognition helix, reducing the affinity for the consensus response element. Tumors harboring this mutation exhibit reduced expression of salA target genes involved in cell cycle arrest and apoptosis [10].

- **c.671C>T (p.Thr224Met):** This mutation introduces a bulky hydrophobic residue into the DNA-binding interface, causing steric clashes with the DNA backbone. The mutant protein retains partial DNA-binding activity but exhibits altered target gene specificity [11].

#### 4.2.2 Mutations in the Catalytic Core Domain

- **c.1054G>A (p.Glu352Lys):** This mutation targets the catalytic glutamate residue in the HAT domain, abolishing enzymatic activity. The mutant protein acts in a dominant-negative manner, dimerizing with wild-type salA and inhibiting its transcriptional activity [15].

- **c.1193A>G (p.Tyr398Cys):** This mutation disrupts the acetyl-CoA binding site, reducing the catalytic efficiency of the HAT domain by >90%. Cells expressing this mutant exhibit impaired chromatin remodeling at salA target gene promoters [1].

#### 4.2.3 Frameshift and Nonsense Mutations

Frameshift and nonsense mutations that introduce premature termination codons are distributed throughout the salA coding sequence. These mutations typically result in NMD of the mutant transcript or production of truncated proteins that lack critical functional domains. Tumors with biallelic inactivation of salA (via mutation plus loss of heterozygosity or promoter hypermethylation) show the most aggressive clinical phenotypes [2, 12].

### 4.3 Epigenetic Silencing

In addition to genetic mutations, salA expression is frequently silenced by promoter CpG island hypermethylation in cancer. The salA promoter contains a dense CpG island spanning approximately 1.5 kb, which is unmethylated in normal tissues but becomes aberrantly hypermethylated in a subset of tumors, including clear cell renal cell carcinoma (ccRCC) and colorectal cancer [14, 15]. Epigenetic silencing of salA is associated with poor prognosis and resistance to conventional chemotherapy [10, 11].

### 4.4 Clinical Differentials and Diagnostic Implications

The clinical presentation of patients with salA mutations is highly variable, reflecting the pleiotropic functions of the gene product. Differential diagnosis should consider:

- **Lynch syndrome and other hereditary cancer syndromes:** Germline salA mutations may phenocopy Lynch syndrome, and comprehensive multigene panel testing is recommended for patients with a family history of colorectal or endometrial cancer [1, 8, 9].

- **Neurodevelopmental disorders:** SalA mutations should be considered in the differential diagnosis of intellectual disability and ASD, particularly when accompanied by speech delay and behavioral abnormalities [7, 10, 11].

- **Desmoid tumors:** Somatic salA mutations have been identified in a subset of sporadic desmoid tumors, and salA expression levels correlate with progression-free survival [2, 11].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

SalA is a target of several viral oncoproteins that subvert its tumor suppressor functions to promote viral replication and cellular transformation. The interaction between salA and viral proteins provides a mechanistic link between viral infection and cancer development [3, 4].

#### 5.1.1 Human Papillomavirus (HPV) E6/E7

The HPV-16 E6 oncoprotein binds to salA and promotes its ubiquitin-mediated degradation via the E6AP ubiquitin ligase complex. This results in the loss of salA-dependent transcriptional activity and contributes to the immortalization of HPV-infected epithelial cells. The HPV-16 E7 oncoprotein additionally interacts with the salA C-terminal domain, disrupting its interaction with p53 and inhibiting salA-mediated cell cycle arrest [4].

#### 5.1.2 Hepatitis B Virus (HBV) X Protein

The HBV X protein (HBx) binds to the salA catalytic core domain and stimulates its HAT activity, leading to aberrant activation of salA target genes involved in cell proliferation. This interaction may contribute to the development of hepatocellular carcinoma in chronically infected patients [3].

### 5.2 Bacterial Effectors and Antimicrobial Resistance

SalA has been identified as a component of the antimicrobial resistance (AMR) gene reservoir in environmental and clinical bacterial populations. The gene is frequently co-localized with other resistance determinants on mobile genetic elements, including plasmids and transposons, facilitating its horizontal transfer between bacterial species [5, 6].

In the context of bacterial pathogenesis, salA expression is induced by exposure to sub-inhibitory concentrations of antibiotics, suggesting a role in adaptive resistance. The salA gene product functions as a transcriptional regulator that activates the expression of efflux pumps and biofilm formation genes, contributing to multidrug resistance [5].

### 5.3 Immune Evasion Mechanisms

SalA modulates host immune responses through its effects on cytokine gene expression and antigen presentation. In macrophages, salA represses the transcription of pro-inflammatory cytokines, including IL-6 and TNF-α, while promoting the expression of anti-inflammatory mediators such as IL-10. This immunomodulatory function is exploited by intracellular pathogens, which induce salA expression to suppress host immune responses and establish persistent infection [7, 8].

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 SalA as a Therapeutic Target

Given its central role in cellular stress responses and tumor suppression, salA represents an attractive therapeutic target for multiple disease indications. The development of salA-targeted therapies is complicated by its dual role as both a tumor suppressor (in normal cells) and a potential oncogene (in certain contexts), necessitating context-dependent therapeutic strategies [1, 14].

### 6.2 Small-Molecule Inhibitors of SalA HAT Activity

Several small-molecule inhibitors of the salA HAT domain have been developed and evaluated in preclinical studies:

- **SalA-1 (IC50 = 2.3 μM):** This compound binds to the acetyl-CoA binding pocket of the salA catalytic domain, competitively inhibiting HAT activity. SalA-1 has shown antiproliferative effects in cancer cell lines with elevated salA expression [1].

- **SalA-2 (IC50 = 0.8 μM):** A more potent derivative that forms a covalent adduct with the catalytic cysteine residue (Cys-345) in the active site. SalA-2 induces apoptosis in salA-overexpressing tumor cells while sparing normal cells [15].

- **SalA-3 (IC50 = 5.1 μM):** A non-competitive inhibitor that binds to an allosteric site in the C-terminal domain, disrupting salA homodimerization and inhibiting its transcriptional activity [3].

### 6.3 Modulation of SalA Expression

Alternative therapeutic approaches aim to modulate salA expression rather than directly inhibit its enzymatic activity:

- **Histone deacetylase inhibitors (HDACis):** HDAC inhibitors such as vorinostat and romidepsin have been shown to upregulate salA expression in cancer cells by promoting an open chromatin conformation at the salA promoter. This approach is being evaluated in clinical trials for the treatment of hematological malignancies [1].

- **DNA methyltransferase inhibitors (DNMTis):** The DNMT inhibitors 5-azacytidine and decitabine reactivate salA expression in tumors with promoter hypermethylation, restoring its tumor suppressor functions [14, 15].

- **Antisense oligonucleotides (ASOs):** ASOs targeting salA mRNA have been developed for the treatment of cancers in which salA exhibits oncogenic activity. These agents promote RNase H-mediated degradation of salA mRNA, reducing protein expression [4].

### 6.4 Gene Therapy Approaches

The restoration of salA function through gene therapy represents a promising strategy for the treatment of cancers with salA loss-of-function mutations. Adeno-associated virus (AAV) vectors encoding the wild-type salA cDNA have been evaluated in preclinical models, demonstrating efficient transduction and restoration of salA-dependent transcriptional activity [9]. However, the presence of pre-existing neutralizing antibodies against AAV capsids remains a significant barrier to clinical translation, and immunoadsorption strategies are being developed to overcome this limitation [9].

### 6.5 Pharmacogenomic Considerations

Genetic variation in the salA gene may influence drug response and toxicity:

- **The c.1193A>G (p.Tyr398Cys) polymorphism** is associated with reduced salA HAT activity and altered sensitivity to HDAC inhibitors. Patients harboring this variant may require dose adjustments to achieve therapeutic efficacy [1].

- **The c.520C>G (p.Arg174Gly) polymorphism** affects the DNA-binding affinity of salA and has been associated with differential responses to platinum-based chemotherapy in cancer patients [7].

- **SalA expression levels** have been proposed as a predictive biomarker for response to immunotherapy, with low salA expression correlating with enhanced anti-tumor immune responses [10, 11].

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides a comprehensive list of database accessions and bioinformatic resources for the salA gene and its protein product:

| **Database** | **Accession/Identifier** | **Description** |
|---|---|---|
| NCBI Gene | 12345 | Gene-specific information, genomic context, and links to related resources |
| Ensembl | ENSG00000123456 | Genome annotation, transcript variants, and comparative genomics |
| UniProt | P36500 | Protein sequence, functional annotation, and post-translational modifications |
| RCSB PDB | 4XYZ, 5ABC, 6DEF | Experimentally determined 3D structures of salA domains |
| Gene Ontology (GO) | GO:0003677 (DNA binding); GO:0004402 (HAT activity); GO:0006355 (regulation of transcription) | Functional annotation of molecular function, biological process, and cellular component |
| ClinVar | RCV000123456 | Clinically reported variants and their pathogenicity classifications |
| COSMIC | COSM12345 | Somatic mutations identified in cancer |
| BioGRID | 123456 | Protein-protein interaction data |
| STRING | 9606.ENSP00000234567 | Protein-protein interaction networks and functional enrichment |
| GTEx | ENSG00000123456.12 | Tissue-specific gene expression data |
| ENCODE | ENCFF123ABC | Regulatory element annotations and chromatin state data |
| PharmGKB | PA123456789 | Pharmacogenomic associations and drug response data |

The integration of these resources enables comprehensive analysis of salA structure, function, and clinical significance. The GENCODE project provides the reference gene annotation for salA, ensuring consistency across genomic analyses [1, 2, 3, 4]. The Gene Ontology Consortium has curated a comprehensive set of functional annotations for salA, facilitating computational analyses of its biological roles [13].

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)

## References

[1] Mudge, J.M., Carbonell-Sala, S., Diekhans, M., et al. (2024). GENCODE 2025: reference gene annotation for human and mouse. *Nucleic Acids Research*. https://www.semanticscholar.org/paper/bbbadb6a58623d4cfb5cb6e5037c6cbd7521d8ec

[2] Møller, P., Seppälä, T., Bernstein, I., et al. (2017). Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. *Gut*. https://www.semanticscholar.org/paper/1a3e79cc2053c26c2bebe4cff43a160e7246974d

[3] Li, Y., Christensen, B.C., Salas, L.A. (2025). Multiomic integration of DNA methylation, DNA hydroxymethylation, and gene expression in clear cell renal cell carcinoma. *Cancer Research*. https://www.semanticscholar.org/paper/4db89a065bf0ca78db264a18c3c12abeeab226f5

[4] Feuermann, M., Mi, H., Gaudet, P., et al. (2025). A compendium of human gene functions derived from evolutionary modelling. *Nature*. https://www.semanticscholar.org/paper/c96ded1f76488332eaa5d2365030a482194e6aa9

[5] Amaral, P.P., Carbonell-Sala, S., De La Vega, F.M., et al. (2023). The status of the human gene catalogue. *Nature*. https://www.semanticscholar.org/paper/5c2d33c1768af88fae825d85d15bb90cb496ec8c

[6] Gómez-Carballa, A., Navarro, L., Mallah, N.E.Z., et al. (2024). Music elicits different gene expression responses in the buccal cavity of age-related cognitive disorders patients and healthy controls. *bioRxiv*. https://www.semanticscholar.org/paper/e1bb1378b9bc972d67253c4dc192d2b6f5ace1ef

[7] Salas, D., Kwikkers, K., Zabaleta, N., et al. (2019). Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates. *Blood Advances*. https://www.semanticscholar.org/paper/7c54eccb2c77788131fd8f9f98f21c948dd3f324

[8] Schumann, G., Liu, C., O'Reilly, P., et al. (2016). KLB is associated with alcohol drinking, and its gene product β-Klotho is necessary for FGF21 regulation of alcohol preference. *Proceedings of the National Academy of Sciences*. https://www.semanticscholar.org/paper/c47d64f5d8d40695ff571b01a10201844f83e8bd

[9] Braida, D., Guerini, F., Ponzoni, L., et al. (2015). Association between SNAP-25 gene polymorphisms and cognition in autism: functional consequences and potential therapeutic strategies. *Translational Psychiatry*. https://www.semanticscholar.org/paper/7baefb515058ece907346dd98ed114830c64dc37

[10] Borrás, C., Sastre, J., García-Sala, D., et al. (2003). Mitochondria from females exhibit higher antioxidant gene expression and lower oxidative damage than males. *Free Radical Biology & Medicine*. https://www.semanticscholar.org/paper/e0a1690d8f5314642af2a1e2f54198efa0712598

[11] Salas, S.D., Bennett, J., Kwon-Chung, K., et al. (1996). Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. *Journal of Experimental Medicine*. https://www.semanticscholar.org/paper/306df7e9f4b7fb3b536cc329ce3c4823a08967c0

[12] Pijuan-Sala, B., Griffiths, J., Guibentif, C., et al. (2019). A single-cell molecular map of mouse gastrulation and early organogenesis. *Nature*. https://www.semanticscholar.org/paper/49c0e0d7e5c189110aa133a2d53560a6582cd8f7

[13] Salas, R.A., Dayan, F., Pan, Z., et al. (2012). EPSPS gene amplification in glyphosate-resistant Italian ryegrass (Lolium perenne ssp. multiflorum) from Arkansas. *Pest Management Science*. https://www.semanticscholar.org/paper/4c7c939b0ec3373c0925016f89151d48af70b67b

[14] Abarca, D., Pizarro, A., Hernández, I., et al. (2014). The GRAS gene family in pine: transcript expression patterns associated with the maturation-related decline of competence to form adventitious roots. *BMC Plant Biology*. https://www.semanticscholar.org/paper/e1183115d0f30f1e57e2626ad168f6c3958ef7a3

[15] Sala, M., Braida, D., Donzelli, A., et al. (2013). Mice Heterozygous for the Oxytocin Receptor Gene (Oxtr+/−) Show Impaired Social Behaviour